Literature DB >> 17575026

Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.

William S Baek, Asad Bashey, Geoffrey L Sheean.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17575026      PMCID： PMC2117664          DOI： 10.1136/jnnp.2006.093567

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Rituximab for myasthenia gravis developing after bone marrow transplant.

Authors:  F Zaja; D Russo; G Fuga; G Perella; M Baccarani
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

2.  Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma.

Authors:  Kazutaka Takagi; Akira Yoshida; Hiromichi Iwasaki; Hitoshi Inoue; Takanori Ueda
Journal:  Ann Hematol       Date:  2005-05-04       Impact factor: 3.673

3.  Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.

Authors:  Berit Hain; Karin Jordan; Marcus Deschauer; Stephan Zierz
Journal:  Muscle Nerve       Date:  2006-04       Impact factor: 3.217

4.  Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

Authors:  Nancy L Monson; Petra D Cravens; Elliot M Frohman; Kathleen Hawker; Michael K Racke
Journal:  Arch Neurol       Date:  2005-02

5.  Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.

Authors:  Ajeet Gajra; Neerja Vajpayee; Sara J Grethlein
Journal:  Am J Hematol       Date:  2004-10       Impact factor: 10.047
  5 in total
  11 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Rituximab Treatment in Myasthaenia Gravis: Report of two paediatric cases.

Authors:  Roshan Koul; Amna Al-Futaisi; Rana Abdelrahim; Renjith Mani; Reem Abdwani; Abdullah Al-Asmi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-09-09

3.  Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.

Authors:  Richard J Nowak; Daniel B Dicapua; Nazlee Zebardast; Jonathan M Goldstein
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 4.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 5.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

Review 6.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

7.  Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Authors:  Enrico C Lallana; Camilo E Fadul
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

8.  Autoimmune neuromuscular disorders in childhood.

Authors:  Hugh J McMillan; Basil T Darras; Peter B Kang
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

9.  Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.

Authors:  Sreenivasa Rao Sudulagunta; Mona Sepehrar; Mahesh Babu Sodalagunta; Aravinda Settikere Nataraju; Shiva Kumar Bangalore Raja; Deepak Sathyanarayana; Siddharth Gummadi; Hemanth Kumar Burra
Journal:  Ger Med Sci       Date:  2016-10-13

Review 10.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.